论文部分内容阅读
胸苷磷酸化酶(TP)是氟尿嘧啶的前体药物活化生成氟尿嘧啶的关键酶,TP还能催化氟尿嘧啶向其活性代谢产物转化,提高抗嘧啶类药物的敏感性;肿瘤组织高表达TP是细胞发生恶性转化后的伴随事件,因此使用卡培他滨(CAP)等化疗可选择性发挥细胞毒作用并提高疗效。多数化疗药物如铂类对宫颈癌TP表达均有上调作用,在联合抗嘧啶类药物行宫颈癌联合化疗中,就如何调节和应用TP,能否利用这些变化规律寻找疗效确切、用药方便、毒性较低的宫颈癌新辅助化疗方案,可否序贯化疗等问题的可行性做一综述。
Thymidine phosphorylase (TP) is the key enzyme of fluorouracil prodrug activated to produce fluorouracil, TP can also catalyze the conversion of fluorouracil to its active metabolite, and improve the sensitivity of anti-pyrimidine drugs; TP is highly expressed in tumor tissue Malignant transformation associated incident, so the use of capecitabine (CAP) and other chemotherapy can selectively play a cytotoxic effect and improve efficacy. Most chemotherapeutics, such as platinum, have an upregulation of TP expression in cervical cancer. In combination with anti-pyrimidine drugs, cervical cancer combined with chemotherapy, how to adjust and apply TP, whether these changes can be used to find the exact effect, convenient medication, toxicity Low cervical neoadjuvant chemotherapy regimen, whether chemotherapy can be sequential issues such as the feasibility of review.